Frank van Haren: ’The early results of our trials show inhaled heparin is safe and effective.’
Frank van Haren: 'The early results of our trials show inhaled heparin is safe and effective.' - A widely available and affordable drug, heparin, limits lung damage when inhaled by COVID-19 patients, according to world-first findings by researchers from The Australian National University (ANU). The researchers are coordinating multiple studies tracking hospital patients infected with SARS-CoV-2 in 13 countries who were given doses of inhaled heparin. ANU study lead Professor Frank van Haren said initial results indicate the drug could be "a promising treatment" and also "a possible preventative against the virus". Breathing and oxygen levels improved in 70 per cent of the patients after they inhaled a course of heparin, and their symptoms improved according to the World Health Organization (WHO) COVID symptoms scale. "There is still an urgent need for an effective treatment of COVID-19 and the early results of our trials show inhaled heparin is safe and effective," Professor van Haren said. - "This drug is already available in hospitals all over the world and it is a very inexpensive drug.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
